PRESS RELEASE
25 November 2026 10:00:00 CET

Alzinova and Cellectricon enter into collaboration to develop a new assay platform for Alzheimer's disease research

Alzinova AB ("Alzinova" or the "Company") today announces that the Company has entered into a collaboration agreement with Cellectricon AB to develop a new cell-based assay platform for Alzheimer's disease research. Alzinova contributes specialist expertise in amyloid-beta and research materials, while Cellectricon contributes expertise in neurobiological assay methods. Through the collaboration, Alzinova will gain access to assay data that may deepen its understanding and support the Company's continued research and drug development. Alzinova retains its rights to its own research materials and to results relating to the Company's drug candidates. Alzinova's commitments are covered by the existing budget and will not affect the resources allocated to the Company's clinical Phase IIa study, ADVANCE.

The assay platform is intended to enable studies of how amyloid-beta derived from patients with Alzheimer's disease affects neuronal function and synaptic structures, as well as to evaluate how antibodies affect Alzheimer's disease-related toxicity. The objective is to establish a tool that can support research and drug development in the field of Alzheimer's disease.

Through the collaboration, Cellectricon aims to deepen its knowledge and broaden its service offering within Alzheimer's disease research. For Alzinova, the collaboration brings access to Cellectricon's expertise in cell-based models and functional assays of neurons.

"*We aim to broaden our offering in the Alzheimer's disease field with an assay method that combines measurements of neuronal function with analysis of synaptic structures. Alzinova's specialist expertise in amyloid-beta and the research materials contributed by the Company are valuable components of this work*," says Mattias Karlsson, CEO of Cellectricon.

"*Cellectricon's interest in utilising our specialist expertise and research materials demonstrates external interest in the assets we have built within the Alzheimer's disease field. At the same time, we gain access to assay data that may support our continued research and drug development, without affecting the resources allocated to ADVANCE*," comments Tord Labuda, CEO of Alzinova.

For further information, please contact:
Tord Labuda, CEO
E-mail: **ir@alzinova.com**

About Cellectricon AB

Cellectricon AB is a Swedish company based in Mölndal, offering specialised research services for early-stage drug development in neuroscience. The Company combines expertise in neurobiology, cell-based models, advanced microscopy and functional assays to develop customised assay methods in collaboration with pharmaceutical and biotechnology companies. Its services include fundamental disease research, early-stage toxicity testing, target identification and validation, as well as the identification and optimisation of drug candidates. For more information, please visit **www.cellectricon.com**.

About Alzinova

Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, with a focus on targeting toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 40 million people affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, as well as the diagnostic project ALZ-401, which aims to develop a blood test to identify an increased risk of Alzheimer's disease before symptoms appear. The goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: **www.alzinova.com**

Attachments

Alzinova and Cellectricon enter into collaboration to develop a new assay platform for Alzheimer’s disease research